Identity on this record
Chemical name: Retatrutide (LY3437943).
Common synonyms: LY3437943, GLP-1/GIP/glucagon triple receptor agonist peptide.
CAS number: 2381089-83-2 (registry entry).
Molecular formula: C221H342N46O68.
Molecular weight: 4731.33 g/mol.
Appearance: White to off-white lyophilised powder.
Catalog strengths: 5 / 10 / 15 / 20 / 30 / 100 mg GLP-3 RT lyophilised vials.
Those identifiers describe Retatrutide as a substance. They do not describe a particular vial. The vial is identified by the name, the nominal fill, and the lot number on its label, checked against the published certificate.
What the catalogue actually sells
GLP-3 RT 5mg (Reta) is the 5 mg lyophilized unit, listed at AED 299 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 10mg (Reta) is the 10 mg lyophilized unit, listed at AED 449 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 15mg (Reta) is the 15 mg lyophilized unit, listed at AED 549 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 20mg (Reta) is the 20 mg lyophilized unit, listed at AED 649 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 30mg (Reta) is the 30 mg lyophilized unit, listed at AED 849 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 100mg (Reta) is the 100 mg lyophilized unit, listed at AED 1,899 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light.
Prices are merchandise prices in AED, exclusive of VAT. VAT is added at checkout. A price on this summary is the figure on the product record for Retatrutide, not a delivered-cost quote. Ordering context that already exists for this compound: Retatrutide requisition and receiving.
Lots and certificates
Lot 20280309 for GLP-3 RT 10mg (Reta) is a Freedom Diagnostics report. The published record states 99.94%. Figures printed on the report: Purity (HPLC-UV) 99.94%; Identity (LC-MS) Confirmed; Net content 13.59 mg. Method line on that report: HPLC-UV / LC-MS. The laboratory file is linked from the certificate page. Open GLP-3 RT 10mg (Reta) certificate or match lot 20280309 in batch verification. That report qualifies this lot only.
Lot VL-GLP3-20260317 is the catalogue certificate for GLP-3 RT 10mg (Reta). Read it on GLP-3 RT 10mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
Lot VL-GLP3RT100-20261020 is the catalogue certificate for GLP-3 RT 100mg (Reta). Read it on GLP-3 RT 100mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
Lot VL-GLP3RT15-20260917 is the catalogue certificate for GLP-3 RT 15mg (Reta). Read it on GLP-3 RT 15mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
Lot VL-GLP3RT20-20260801 is the catalogue certificate for GLP-3 RT 20mg (Reta). Read it on GLP-3 RT 20mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
Lot VL-GLP3RT30-20260917 is the catalogue certificate for GLP-3 RT 30mg (Reta). Read it on GLP-3 RT 30mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
Lot VL-GLP3RT5-20260917 is the catalogue certificate for GLP-3 RT 5mg (Reta). Read it on GLP-3 RT 5mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
Retatrutide has both a laboratory report and catalogue certificates. Freedom Diagnostics lot 20280309 is the third-party file. The other lot numbers are catalogue certificates for their own fills. Match the printed lot. Do not treat one purity line as the result for every vial.
How the compound record describes the literature
Retatrutide (LY3437943) advanced through Eli Lilly clinical development pipelines; research supply interest focuses on reference material for analytical and preclinical model work — not clinical use.
Topics named on the Retatrutide record, as literature context rather than as outcomes VaultLabs claims: Receptor binding assays; Glucose homeostasis models (preclinical); Energy expenditure literature reviews; In vitro receptor pharmacology.
That is context for identifying Retatrutide. It is not a claim that a vial produces a result in a person, an animal, or a study VaultLabs has not published. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
Points the monograph already states
Points already written on the Retatrutide monograph, so a reader can check them against that page:
Development designation LY3437943; CAS registry number 2381089-83-2.
Molecular formula C221H342N46O68; molecular weight 4731.33 g/mol — substantially larger than most catalog peptides.
Described as a triple agonist acting at the GLP-1, GIP and glucagon receptors, distinguishing it from single- and dual-agonist incretin peptides.
Investigational only: it is in clinical trials and has not been approved by the UAE Ministry of Health and Prevention, the FDA, the EMA or any comparable regulator.
Its size makes analytical characterisation and handling more demanding than for a short peptide; LC-MS confirmation is particularly valuable for this material.
Dispatch and the research-use boundary
VaultLabs dispatches Retatrutide from Dubai. Orders leave fulfillment within 24 hours, 7 days a week. Standard delivery is AED 35 to every emirate, and delivery is free when the post-discount merchandise subtotal is AED 500 or more. Checkout shows the fee for the address entered. All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
The full narrative record is the Retatrutide compound monograph. Handling of the sealed unit is the Retatrutide storage guide. Questions are collected on the Retatrutide FAQ. How it differs from neighbouring records is the Retatrutide comparison.